Excision BioTherapeutics Appoints Senior CFO Christine Silverstein as CFO


Receive instant alerts when news about your stocks is available. Claim your 1-week free trial for StreetInsider Premium here.

SAN FRANCISCO, May 3, 2021 (GLOBE NEWSWIRE) – Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR antiviral therapies to improve the lives of patients, today announced the appointment of Christine Silverstein to the role financial director. Silverstein joins Excision with over 15 years of financial leadership and financial market expertise in the biopharmaceutical industry.

“We recently completed our Series A funding round allowing us to advance our lead candidate, EBT-101, into a phase 1/2 clinical trial in patients with chronic HIV infection and to fund the development of preclinical candidates targeting JC virus for progressive multifocal leukoencephalopathy (PML), herpes simplex virus and chronic hepatitis B, ”said Daniel Dornbusch, CEO of Excision. “Christine is a recognized expert in managing the financial growth of emerging biopharmaceutical companies. We look forward to his operational and strategic advice as we continue to execute all of our clinical and preclinical programs. “

“Excision uses CRISPR for its naturally evolved goal of attacking viral infections, and takes advantage of this elegant approach in its portfolio of programs spanning a range of viral diseases,” said Christine Silverstein. “I look forward to leading the finance team and working with everyone at Excision to help fulfill its mission to bring transformative CRISPR-based therapies to patients to cure viral infectious diseases.”

Silverstein is a seasoned corporate finance executive with invaluable experience in private and public biopharmaceutical companies. Most recently, she served as Chief Financial Officer of Emendo Biotherapeutics, a next-generation gene-editing company that was acquired in December 2020 by AnGes, Inc. Chief Financial Officer of the fully integrated cell and gene therapy company , and continues to serve as a member of its board of directors. Prior to joining Abeona, she led internal financial markets strategy at various public companies, including Relmada Therapeutics, Inc., an advanced biotechnology company that deals with diseases of the central nervous system (CNS). Silverstein has also held senior management positions at New York-based biotech venture capital fund, SCO Capital Partners and financial market advisory firms, where she was instrumental in advising clients. on transaction considerations and the formulation of effective listing and financing strategies in the United States. Silverstein began her career in the financial services industry as an investment advisor at Royal Alliance Associates. A member of CHIEF and Women in Bio (WIB), two esteemed networks of outstanding women leaders, Silverstein holds a BS from the Peter Tobin College of Business at St. John’s University and has obtained various accreditations from the Financial Industry Regulatory Authority (FINRA).

About Excision BioTherapeutics, Inc.

Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to treat viral infectious diseases. FGC aims to improve the lives of patients with chronic illnesses by eliminating the viral genomes of infected individuals. By using CRISPR in a unique way, the Company has already demonstrated the first functional remedy against HIV in animals. Excision develops technologies and intellectual property developed at Temple University and UC Berkeley. Excision is located in San Francisco, California and is backed by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures , and Gaingels. For more information, please visit www.excision.bio.


InvestorsEric AndoBurns McClellan, Inc. [email protected]

MediaRyo Imai / Robert Flamm, Ph.D. Burns McClellan, Inc. [email protected] / [email protected]

Source: BioTherapeutics excision

Leave A Reply

Your email address will not be published.